Mechanism of Action via Opioid Receptors
Classical agents, such as codeine, act as opioid receptor agonists in the digestive tract. By binding to these receptors, they trigger a cascade of reactions that fundamentally alter gastrointestinal function.
First, codeine specifically affects the muscular apparatus: it significantly enhances segmental (spasmodic) motility while suppressing propulsive peristalsis, which normally drives the bolus forward. Second, the drug increases the baseline tone of the intestinal smooth muscle and its sphincters. Third, codeine interferes with secretory function by actively inhibiting the secretion of water and electrolytes into the intestinal lumen.
The net result of these processes is a marked deceleration of chyme transit through the intestine. However, codeine can penetrate the central nervous system, which limits its clinical use primarily to specific indications rather than routine antidiarrheal therapy.
Synthetic Agonists (A Safe Alternative)
This pharmacological category focuses on motility-inhibiting drugs emphasizing safety compared to classical opiates (such as morphine or codeine).
A prominent representative of this group is loperamide (trade name Imodium). It is a synthetic opioid receptor agonist whose antidiarrheal effect is functionally similar to codeine (reduced motility). However, its pharmacokinetics have critical differences. Loperamide has virtually no effect on the CNS because it is physically unable to accumulate past the blood-brain barrier (BBB). The reason is that the loperamide molecule is a substrate for P-glycoprotein. This transport protein acts as a pump, continuously 'effluxing' the drug from brain tissue back into the systemic circulation. Consequently, loperamide does not cause tolerance or physical dependence. Potential adverse effects include nausea, dizziness, and predictable constipation.
Another drug in this group is nufenoxole. Its basic mechanism of action is similar to loperamide, but its clinical profile is geared toward fluid regulation. Nufenoxole predominantly inhibits the secretion of water and salts into the GI lumen while simultaneously enhancing fluid absorption (reabsorption) from the contents of both the small and large intestines.
Peripheral Opioid Receptor Antagonists
In clinical practice, physicians frequently encounter the flip side of opioid action—severe constipation (opioid-induced constipation). This problem is particularly relevant for cancer patients receiving palliative care with potent narcotic analgesics.
To manage these conditions, methylnaltrexone is used. Chemically, it is a naltrexone derivative with one critically important feature: methylnaltrexone does not cross the blood-brain barrier.
Its pharmacological significance lies in selectively blocking peripheral opioid receptors exclusively within the intestinal wall. This restores normal motility and relieves constipation without affecting the central analgesic effects of opioids that are vital for patients undergoing palliative care.